Microbial Metabolite-Mediated α-Synuclein Disaggregation

Mechanistic description

Specific gut bacterial strains produce short-chain fatty acids (SCFAs) that cross the blood-brain barrier and directly modulate α-synuclein aggregation through epigenetic modifications of chaperone proteins. Therapeutic supplementation with SCFA-producing bacteria could prevent or reverse pathological protein aggregation in PD.

Mechanism / pathway

SNCA, HSPA1A, DNMT1
→
Alpha-synuclein aggregation / synaptic vesicle
→
neurodegeneration

Evidence for (5)

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.

PMID:34729301 2021 Acta Pharm Sin B
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.

PMID:35287553 2022 Autophagy
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease therapy.

PMID:40245457 2025 Biomaterials
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.

PMID:40042514 2025 Alzheimers Dement
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition.

PMID:40634788 2025 Mol Neurobiol

Evidence against (2)

Short-chain fatty acids produced by gut microbiota promoted microglial activation and motor deficits in an alpha-synuclein Parkinson model, contradicting a uniformly protective SCFA/disaggregation model.

PMID:27912057 2016 Cell
Reviews of SCFAs, alpha-synuclein, neuroinflammation, and redox stress describe bidirectional and context-dependent effects rather than direct disaggregation evidence.

PMID:38377788 2024 Redox Biol

Evidence matrix

5 supporting 2 contradicting

71% supporting

Supporting

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. PMID:34729301 · 2021 · Acta Pharm Sin B
Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models. PMID:35287553 · 2022 · Autophagy
A ROS-Responsive nanoparticle for nuclear gene delivery and autophagy restoration in Parkinson's disease therapy. PMID:40245457 · 2025 · Biomaterials
Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort. PMID:40042514 · 2025 · Alzheimers Dement
The Crosstalk Between Sepsis-Associated Encephalopathy and Alzheimer's Disease: Identifying Potential Biomarkers and Therapeutic Targets for Cognition. PMID:40634788 · 2025 · Mol Neurobiol

Contradicting

Short-chain fatty acids produced by gut microbiota promoted microglial activation and motor deficits in an alpha-synuclein Parkinson model, contradicting a uniformly protective SCFA/disaggregation model. PMID:27912057 · 2016 · Cell
Reviews of SCFAs, alpha-synuclein, neuroinflammation, and redox stress describe bidirectional and context-dependent effects rather than direct disaggregation evidence. PMID:38377788 · 2024 · Redox Biol

Top-ranked evidence

trust_score × relevance_score × exp(-recency_weight × recency_days / 365)

Supports · top 3

#1 paper-077768883bd4 0.466 trust 0.50 · rel 1.00 · 86d
#2 paper-2b9fe2e6ce03 0.466 trust 0.50 · rel 1.00 · 86d
#3 paper-86262c6ce133 0.466 trust 0.50 · rel 1.00 · 86d

38 total ranked · scidex.hypotheses.evidence_ranking

Cite this hypothesis

Citation

etl-backfill (2026). Microbial Metabolite-Mediated α-Synuclein Disaggregation. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-74777459

BibTeX

@misc{scidex_hypothesis_h7477745,
  title        = {Microbial Metabolite-Mediated α-Synuclein Disaggregation},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-74777459},
  note         = {SciDEX artifact hypothesis:h-74777459}
}